Compare SATS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATS | EXAS |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 19.3B |
| IPO Year | 2007 | N/A |
| Metric | SATS | EXAS |
|---|---|---|
| Price | $119.92 | $102.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $127.00 | $80.25 |
| AVG Volume (30 Days) | ★ 5.0M | 3.0M |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,175,913,000.00 | $3,082,033,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $13.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $14.90 | $38.81 |
| 52 Week High | $119.80 | $102.66 |
| Indicator | SATS | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 75.08 | 83.45 |
| Support Level | $107.59 | $101.51 |
| Resistance Level | $117.15 | $101.89 |
| Average True Range (ATR) | 4.60 | 0.34 |
| MACD | 0.04 | -0.93 |
| Stochastic Oscillator | 94.33 | 96.59 |
Satellite television provides the bulk of EchoStar's revenue. The firm serves about 5 million US satellite customers, about 10% of the traditional television market. It also serves 2 million customers under the Sling brand. EchoStar has also amassed an extensive portfolio of spectrum licenses and is building a nationwide wireless network. It acquired Sprint's prepaid business, serving approximately 7 million customers, primarily under the Boost brand. The firm has agreed to sell a portion of its wireless licenses to AT&T and will rely heavily on the AT&T network to serve customers. EchoStar's legacy businesses provide satellite telecom services and equipment to businesses and consumers, including about 800,000 internet customers.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.